Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
2,200 miles. arriving in Miami Beach tomorrow. yeah buddy looking forward. To all things to come @omnihealth, inc.
A big day for exiting I see not everybody has the patience this stock requires.
Good morning OMHE'ERS
Hell yeah it is. it's going places.
I think it's super useful. it's demonstrating that they are working in 2021 on previous communications. toward fruitioned results
Looks like there renting space from wework.
We saw the same popup office setup in california as well.
Agelock biotech, entourage biotech.
Acquiring product relivatrol,"RelieveMD entity ACQUISITION" it's in the pitch deck full on details in my DD packet. it's only a matter of time before we see relivatrol phase 2 studies. We know phase 1 exists a f has taken place.
It's a load of BS it's profit driven and they'le never be forth coming about it.
When they gave me the same speech about how they felt like they were doing me a favor I said did you fly out to the company and do on site research? nope didn't think so. how can you justify telling me I don't know what I'm investing in if you know less than I do?
I asked 43 different ways if there was a workaround. Even the guy on the advanced elite team kind of had this disappointed sad notation to his voice when communicating with me about my concerns on these new changes. everything is going on deaf ears and nothing is being hurt at the top I used to be able to get to the top and now you can't they've put up a huge wall and are ignoring everybody's concerns. it's really ashame to watch a beloved firm go to the s******.
NVM, this is old af I.E. 2010.
I saw this coming 100 miles away. I came here looking for options once JP was interested in Etrade and my oh frucks alarm began blarring...
If you can't be on the buy side how can you audit a company? nevada law 78.125 says I'm entitled to audit a company but you can't audit if you can't build positions to then hold management accountable. should be argued in court to fight these restrictions by various brokers I simple haven't the capital to allocate to addressing big brother over my shoulder.
Nobody needs a baby sitter! eh hem Etrade you listening? If somebody does or think they do then ?? they should stick with higher tiered securities in higher quality exchanges regarding transparency for your incompetence or simply put laziness in doing your homework.
Do you guys remember that video posted by that physician supporting relivatrol? That's all part of the industry connections to the physicians and other opportunities for the company.
For those of you who haven't seen the relivatrol video here it is now;
https://www.dailymotion.com/video/x7uh8xj
Let me try to help you guys understand. The products and the physical location are not what's valuable here it's omnis industry connections and the doctors and physicians that they're connected with for the sale of their products that are coming out through other known subsidiaries of the company. the comparison of Malecon to other pharmacies is completely irrelevant what is relevant is the physicians and the industry connections for malcon in other words malecon is becoming
Bingo. Thus malecon wasn't sold per the claim.
A FULL CHART RESET. yeah buddy.
First investing day of the new yr let's gooooo
Multi yr plan mentioned in PR is well underway based on loads of activity shared in this community. I love that Omni is long term and gives zero frucks about short term shareholder profit. forcing us to endure tax savings.. oh the horror.
2 different experiences.
the first visit solo in 2017. I asked if Andrey was on site they said yes "would you like to see him" I said not if he's busy they said Yes he is I said ok don't worry it's ok.
In 2018 I visited again prior to it closing. les was already planning a visit around the same time "for a personal vacation but did want to visit malecon. so I changed my open schedule accordingly and offered to take him and his gal out to dinner for steak and stock talk.
They "the malecon staff" were never ever once unwelcoming.
if you go back and see my post history my story hasn't changed at all. I'm consistently forth coming and tell the facts period.
The website was updated in 2020.
I emailed the company about the updated website and when they opened my email shortly after the website was taken down.
~many company websites remain blocked to the public but we know they're there because nobody else has taken them registered them elsewhere etc.
The physical location was closed in 2018 around October. I sent a notification to google to remove malecon in both 2019 and 2020 and the company has to rebuttal the claim of closure submitted to googlemaps so they're not taking it down thus someone said something to google.
Nobody and I mean nobody has any substantial evidence to suggest malecon has closed for good.
My due diligence points to a relaunch. And I continue to see momentum and forward progress from the company here and there online including the relivatrol study.
Who started the melecon sale rumor? nobody can verify either way sold or not. it's super annoying that we haven't proof of either or.
we only know of a divestiture to what extent and to what part or all of that business it never said selling it simply said divesting.
Welcome to 2021 $OMHE'ERS.
Let's goo boss welcome to 2021.
The best part nobody sold squat. That says a lot.
"glass clinking" Good morning OMHE'ERS ringing in the new yr. Here's to whatever omni has in store for us.the good "toast" the bad "toast"
3's 4's 5's are becoming slim to none.
So Andrey sells malecons assets to Walgreens/cvs then transfers the wealth to a launching entity "for services rendered" maybe entourage biotech maybe agelock biotech and files chapter 5 debt relief closes malecon and uses holding companies to protect assets. thus ruining malecon and his financials short term granting a clean slate knowing the future value on the relaunch is much greater
More to add to this idea, needs refinement and more detail. but I must rest.
"Speculation"
Could it be the companies management team Tik tok
Filing the bankruptcy chapter 5 creates a stay in court. Issentially wipes the debt of 214,000 due to Black mountain.
The covid chapter 5 debt relief can wipe away up to 2.5M I think I saw online.
and a relaunch on a clean slate with a new management team. with products and more intact. Andrey becomes a shareholder as is already suspected.
it's possible all these actions are highly intentional to clear the books.
obviously highly speculative but plausible.
Omni looks to be going through chapter 5.
https://www.google.com/amp/s/foka-nieuws.nl/2020/12/18/optische-surgical-navigation-system-market-2021-covid-19-impact-analysis-industry-prijs-trend-size-schatting-industry-outlook-business-growth-rapport-latest-research-business-analyse-en-forecast/amp/
Additional information on chapter 5's
When/if they execute CBD/FDA products for chronic pain we will be looking at sector PE ratios 50-100x earnings. Last I looked several months ago the sector was like 87x earnings.
Based on the current conducting of starter studies I personally think we are still potentially a few yrs away from relaunch. I'd love to be wrong though.
Man we get updates in 2021 this thing flies.
Potential pending news/updates.
SUBSIDIARIES
~ ENTOURAGE BIOTECH "TARGET ACQUISITION"
PRODUCTS: "RELIVATROL,RELIEVEMD"
~ AGELOCK BIOTECH "TARGET ACQUISITION"
PRODUCTS: "HEMP VODKA, DRCBD"
~ CELEBRITY BRANDS
"DEALS/PARTNERSHIPS"
~ MALECON PHARMACY
"SOLD/RELAUNCHED"
~RELIEVEMD "PLANNED SUBSIDIARY with $3.25M funding saught for 40% ownership"
we shall see.
Merry Christmas $OMHE'ers.
Looking forward to it.
Each time I reread these press releases I always learn something I missed. Crazy how much info I missed initially back when.
This new distribution agreement represents the latest step towards Omni Health multi-year plan of making its next-generation anti-aging CBD products available for global distribution.
https://www.otcmarkets.com/stock/OMHE/news/Omni-Health-Inc-Announces-37-Million-Euro-Distribution-Agreement-Across-Europe?id=177968
RELIVATROL
https://insights.ovid.com/obstetrics-gynecology/obsgy/2020/05/001/novel-therapeutic-management-post-episiotomy-pain/475/00006250
INTRODUCTION:
Although rates of episiotomy are declining, post-episiotomy pain remains a complication in obstetric care. Current management includes NSAIDs and Benzocaine, but the use of Benzocaine has been linked to iatrogenic methemoglobinemia, with greatest risk in newborns. We hypothesized that a novel drug formulation, currently being investigated in diabetic neuropathy, can be used to attenuate post-episiotomy pain.
METHODS:
This pilot study was conducted in an outpatient obstetrics clinic on postpartum women aged between 18 and 39, who underwent vaginal delivery with episiotomy. Spray bottles with the investigational product were distributed to the patients to use without regulation. A survey to assess post-episiotomy pain using the Visual Analog Scale (VAS) was administered to the patients. Pain attenuation, time to pain attenuation, and quality of pain were measured.
RESULTS:
The cohort consisted of 25 women (including 5 non-responders). In responders, pain was attenuated by 4.0 scale units. Average time to analgesia was 9.25. Average pain ratings after treatment were compared to average pain ratings before treatment using a unidirectional paired sample t test (df=24). The average pain ratings for the entire cohort after administration of Relivatrol© were significantly lower than average pain rating prior to administration t (24)=7.41, P<.0001.
CONCLUSION:
We concluded that Relivatrol© significantly decreases post-episiotomy pain. Being a pilot study had multiple limitations; we developed a protocol for a larger investigation and are currently collecting data involving a greater number of subjects, a control arm, pharmacokinetic parameters, and an analysis of quality of life impact.